Prof. Jae-Ho Yoon: Korea’s ALL Management in the Era of Gene Analysis and Targeted Immunotherapy
Editor’s Note: On October 31, 2025, the International Conference on Cellular Therapy and Biomedical Frontiers, hosted by the Xiong’an Institute for Engineering–Medicine Translational Research of Peking University People’s Hospital and…
2025 FACO | Professors Tetsuya Mitsudomi & Yun Gyoo Lee: Strengthening China–Japan–Korea Collaboration to Address Shared Challenges in Lung Cancer Care
China, Japan, and South Korea have long ranked among the countries with the highest incidence of lung cancer worldwide. With a heavy disease burden, urgent unmet medical needs, and remarkably similar disease characteristics, strengthening trilateral collaboration among these East Asian nations is critical to advancing clinical oncology and addressing shared challenges in lung cancer management.
ESMO China Voice | Prof. Guiying Xu: High Concordance of PIK3CA Mutations Between Primary and Metastatic Lesions in HR+/HER2– Breast Cancer
Editor’s Note The European Society for Medical Oncology (ESMO) 2025 Annual Congress, held in Berlin, Germany from October 17–21, gathered leading global experts to share groundbreaking advances in cancer diagnosis…
ESMO Hot Topic | Professor Zhang Juliang: Long-Term GeparNuevo Follow-Up Reveals Durable Survival Benefits from Durvalumab Neoadjuvant Therapy in Early Triple-Negative Breast Cancer
At the 2025 ESMO Annual Congress, the long-term follow-up results of the GeparNuevo trial (Abstract #292MO) were presented. The data showed that although durvalumab combined with neoadjuvant chemotherapy did not significantly improve the pathological complete response (pCR) rate, it significantly prolonged survival outcomes, including invasive disease-free survival (iDFS), distant disease-free survival (DDFS), and overall survival (OS). Notably, among patients who achieved pCR, the 7-year OS rate reached 100% in the durvalumab group, suggesting that immunotherapy may provide long-term benefits through sustained immune surveillance. Oncology Frontier invited Professor Zhang Juliang from Xijing Hospital, Air Force Medical University, to comment on these findings and discuss strategies for optimizing immunotherapy in early triple-negative breast cancer (TNBC).
Focusing on the Frontier, Gathering Wisdom in Xiong’an | 2025 CRHA Conference on Cell Therapy and Biomedical Frontiers Opens Grandly
Editor’s Note: As autumn brings its golden harvest, scientific progress likewise flourishes. The 2025 Chinese Research Hospital Association Conference on Cell Therapy and Biomedical Frontiers, jointly organized by the Cell…
A New Chapter in Comprehensive Management of Renal Cell Carcinoma | Professors Youyan Guan and Xiongjun Ye Provide In-Depth Insights
On August 22–23, 2025, the 2025 Pujiang Uro-Oncology Conference was held in Shanghai, bringing together leading experts to discuss advances in urologic oncology. This article is based on the pre-conference session presented by Professor Youyan Guan (Cancer Hospital, Chinese Academy of Medical Sciences) and Professor Xiongjun Ye, titled “Comprehensive Management of Renal Cancer Patients.” Their lecture systematically reviewed the evolution of treatment concepts, perioperative and advanced-stage strategies, and the construction of comprehensive management systems, aiming to provide clinical and research colleagues with valuable reference and guidance.
Professor Jiong Hu: Clinical Management of Cytomegalovirus Infection After Transplantation and the Ruijin Protocol
On August 22–23, 2025, the 13th Lu Daopei Hematology Conference was held in Beijing, jointly organized by the Beijing Health Promotion Association and the Guangzhou Kapok Oncology and Rare Disease…
Global Quality, Chinese Evidence | Prof. Jing Cheng: Lerociclib Achieves Continuous Target Inhibition with Balanced Efficacy and Safety
Editor’s Note: On May 29, 2025, the originator, next-generation CDK4/6 inhibitor Lerociclib received approval from China’s National Medical Products Administration (NMPA) for both first-line and second-line indications in HR+/HER2– advanced…